Genmab AS (GMAB) - Total Liabilities
Based on the latest financial reports, Genmab AS (GMAB) has total liabilities worth $7.01 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore GMAB year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Genmab AS - Total Liabilities Trend (2002–2025)
This chart illustrates how Genmab AS's total liabilities have evolved over time, based on quarterly financial data. See Genmab AS free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Genmab AS Competitors by Total Liabilities
The table below lists competitors of Genmab AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MPI Corporation
TWO:6223
|
Taiwan | NT$9.42 Billion |
|
Beiersdorf Aktiengesellschaft
F:BEIA
|
Germany | €4.14 Billion |
|
Tractor Supply Company
NASDAQ:TSCO
|
USA | $8.35 Billion |
|
Hua Xia Bank Co Ltd
SHG:600015
|
China | CN¥4.47 Trillion |
|
Evolution Mining Ltd
AU:EVN
|
Australia | AU$4.39 Billion |
|
POSCO Holdings Inc
F:PKX
|
Germany | €42.89 Trillion |
|
Varun Beverages Limited
NSE:VBL
|
India | Rs62.09 Billion |
|
Bank of Beijing Co Ltd
SHG:601169
|
China | CN¥4.60 Trillion |
Liability Composition Analysis (2002–2025)
This chart breaks down Genmab AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Genmab AS.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genmab AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genmab AS (2002–2025)
The table below shows the annual total liabilities of Genmab AS from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.01 Billion | -23.09% |
| 2024-12-31 | $9.11 Billion | +147.73% |
| 2023-12-31 | $3.68 Billion | +29.68% |
| 2022-12-31 | $2.84 Billion | +16.70% |
| 2021-12-31 | $2.43 Billion | +20.23% |
| 2020-12-31 | $2.02 Billion | +84.49% |
| 2019-12-31 | $1.10 Billion | +145.39% |
| 2018-12-31 | $446.64 Million | +35.04% |
| 2017-12-31 | $330.75 Million | -19.63% |
| 2016-12-31 | $411.54 Million | -1.03% |
| 2015-12-31 | $415.83 Million | -50.13% |
| 2014-12-31 | $833.74 Million | -22.23% |
| 2013-12-31 | $1.07 Billion | -18.15% |
| 2012-12-31 | $1.31 Billion | +21.49% |
| 2011-12-31 | $1.08 Billion | -23.08% |
| 2010-12-31 | $1.40 Billion | +51.63% |
| 2009-12-31 | $924.34 Million | -13.64% |
| 2008-12-31 | $1.07 Billion | -0.48% |
| 2007-12-31 | $1.08 Billion | +445.81% |
| 2006-12-31 | $197.05 Million | -21.70% |
| 2005-12-31 | $251.66 Million | +176.79% |
| 2004-12-31 | $90.92 Million | -2.94% |
| 2003-12-31 | $93.67 Million | -49.08% |
| 2002-12-31 | $183.97 Million | -- |
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more